STEREOSELECTIVE PROCESS FOR THE PREPARATION OF ANTHRACYCLINE DERIVATIVES

Abstract: A stereoselective process for the preparation of a 4′-0-­ tetrahydropyranyl derivative of an anthracycline compound having a daunosamine residue by reacting an anthracycline compound of the formula wherein R represents a hydrogen atom, a halogen atom or a protected hydroxyl group, or an acid addition salt thereof, with 3,4-dihydro-2H-pyran in an inert solvent in the presence of a metal-containing Lewis acid, and isolating the desired stereoisomer by a usual method.

Description: This invention relates to a novel stereoselective process for preparing a 4'-O-tetrahydropyranyl derivative of an anthracycline compound having a daunosamine residue. The anthracycline compounds of the formula I EMI1.1 so far used widely in clinical practice as chemotherapeutic agents are daunomycin of said formula in which R represents a hydrogen atom, and adriamycin of said formula in which P. represents a hydroxyl group. Although daunomycin and adriamycin show considerably potent anticancer activity, they are not entirely satisfactory. In an attempt to discover com- pounds having more potent anticancer activity, various analogues have been provided by various methods, such as fermentation, semi-synthesis, total synthesis and microbiological transformation. The present inventors have also provided useful derivatives of daunomycin and adriamycin which are compounds having a tetrahydropyranyl group at the 4position of the daunosamine residue, i.e. EMI1.2 These 4-0-tetrahydropyranyl compounds are, for example, described in JP-A2-56 494/82 (Jap. Examined Patent Publica tion) and JP-A1-156 300/81 (Jap. Laid-Open Unexamined Patent Publication) Such tetrahydropyranyl compounds include two isomers which are ascribed to the configuration on the C-2 position of the tetrahydropyran-2-yl group, as stated previously. One of the isomers shows a higher Rf value on silica gel thin-layer chromatography using chloroform-methanol (9:1) as a developer (hereinafter referred to as Compounds (b)), and the other shows a lower Rf value on the same chromatography thereinafter referred to as Compounds (a)]. Compound (b), in particular, has been found to have much more potent anticancer activity against tumors in experimental animals than daunomycin and adriamycin have. Its development as a drug for clinical practice has therefore been desired strongly. According to the aforementioned known manufacturing methods, Il'-O-tetrahydropyranyl derivatives of anthracycline compounds have been formed as Compound (a) and Compound (bj each in an approximately equal amount. There has been a demand, therefore, for a process by which Compound (b) showing very potent anticancer activity can be selectively obtained at a high yield among these isomers. It has now been found that tetrahydropyranyl derivatives can be obtained with increased content of Compound (b) without accompanying any decrease in their total yields by using a metal-containing Lewis acid as a catalyst in place of an organic sulfonic acid. This invention relates, therefore, to a process for preparing, at a higher content, a stereoisomer showing a higher Rf value on silica gel thin-layer chromatography using chloroform-methanol (9:1) as a developer, among stereoiso mers ascribed to the configuration on the C-2 position of the tetrahydropyran-2-yl group of a 4'-0-tetrahydropyranyl derivative of an anthracycline compound expressed by the formula (II) EMI3.1 wherein R represents a hydrogen atom, a halogen atom or a protected hydroxyl group, which comprises reacting an anthracycline compound of the formula (I) EMI3.2 wherein R is as defined above, or an acid addition salt thereof, with 3,4-dihydro-2H-pyran in an inert solvent in the presence of a metal-containing Lewis acid. The process of the invention is applicable to anthracycline compounds having a daunosamine residue, such as daunomycins, adriamycins, carminomycins and feudomycins, and derivatives arising from their aglycones (see, for example, The Journal of Antibiotics, Vol. 14, 1596-1607, 1981). Compounds preferred because of their anticancer activity as compounds of the formula (I) derived from daunomycin and adriamycin are, for example, those in which R represents a hydrogen atom, a halogen atom or a protected hydroxyl group. Specifically, there are cited compounds in which said halogen atom is a bromine atom (see, for instance, Japanese Laid-Open Unexamined Patent Publication No. 165300/81 quoted previously), and compounds in which said protected hydroxyl group is a group easily convertible into a hydroxyl group by mild hydrolysis, such as a lower alkanoyl group, an aralkylcarbonyl group, or an aromatic carbonyl group (see, for example, United States Patent No. 3, 803, 124). The latter compounds with the protected hydroxyl group as R should be those which can be converted into tetrahydropyranyl derivatives according to the process of this invention and then subjected to hydrolysis, hydrogenolysis or the like to convert the R into a hydroxy group. Examples of the metal-containing Lewis acids for use in the process of this invention are those halides of typical metals and transition metals (excluding alkali metals and alkaline earth metals) which can be used as Lewis acids. Their typical examples are AlCi3, AlBr3, A1I3, TiCl4, FeC13, SnCl4, ZnCl2, etc. Organometallic compounds which act as Lewis acids, such as (C2H5)2AlCl and CH3A1C12, can also be used as the Lewis acids of this invention. Of these compounds, the use of AlC13, TiC14 and AlBr3 are preferred to form Compound (b) with increased selectivity according to the present invention. The inert solvents for use in the process of this invenntion may be any organic solvents which does not substan tially affect the reaction for forming the tetrahydropyranyl derivative and which can prepare a uniform reaction mixture. Its preferred examples are aprotic polar solvents, such as N,N-dimethylformamide (hereinafter referred to as DMF), dimethyl sulfoxide, tetrahydrofuran, acetonitrile, and nitromethane. Suitable solvents can be selected by considering whether they can form a uniform reaction solvent system, the properties of the starting compound of the formula (I) and the characters of Lewis acid used. The reaction between the compound of formula (I) and 3,4-dihydro-2H-pyran of the formula EMI5.1 in the presence of the Lewis acid is performed in the above mentioned solvent advantageously under mild temperature at which no substantial decomposition of the starting compounds takes place, preferably, at room temperature or below, concretely, a temperature ranging from about -30 to about 300C. Under such conditions, the reaction completes normally in a period of from 2 to 48 hours. The amount of the metal-containing Lewis acid used in converting the compound of the formula (I) into its tetrahydropyranyl derivative can be varied widely depending on the type of the Lewis acid, the reaction conditions, etc. However, it is used in 2 to 10 molar equivalents in general, preferably 4 to 6 molar equivalents, per mol of the compound of the formula (I). The amount of 3,Il-dihydro-2H-pyran for use in the formation of the tetrahydropyranyl derivative is not less than 10 molar equivalents, preferably 100 to 1000 molar equivalents, per mol of the compound of the formula (I). After the reaction is completed, the compound of the formula (II), the tetrahydropyranyl derivative, can be subjected to isolation and purification steps [including dissolution of isomers, i.e., Compound (a) and Compound (b)] by various methods that are known per se. For this purpose, methods that are frequently used in the isolation and purification of anthracycline antibiotics may be employed to isolate the intended compound from the reaction mixture. If the resulting compound has a halogen atom or a protected hydroxyl group as R, it may be hydrolyzed, if desired, without being isolated or purified, whereby a tetrahydropyranyl derivative of adriamycin can be obtained. (For details, see the aforecited patents.) Example 1 Preparation of 4'-O-tetrahydropyran-2-yl-14- bromo-daunomycin 25 mg of 14-bromodaunomycin hydrobromide was dissolved in 2.5 ml of anhydrous DMF, and 25 mg of anhydrous aluminum chloride was added, followed by stirring the mixture for 1 hour at room temperature. During this period, the reaction mixture changed from red into purple. Then, 1 ml of 3,4-dihydro-2H-pyran was added, and the resulting mixture was reacted for 18 hours with stirring at room temperature. Upon completion of the reaction, the reaction mixture was poured into 0.1M sodium bicarbonate containing disodium ethylenediaminetetraacetate [EDTA(2Na)]. After the mixture was stirred for several hours, it was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated to dryness. The resulting crude product was separated chromatographically on a silica gel plate by using chloroform-methanol (9:1) as a developer. The separated spots of the desired compounds were scraped out of the plate, and purified. The yields of Compounds (a) and (b) were as follows: Compound (b) with an Rf value of 0.50 ....,.... 11 mg Compound (a) with an Rf value of 0.33 4 Il mg Example 2 Preparation of 4'-0-tetrahydropyran-2-yl- daunomycin The same procedure as in Example 1 was performed except that daunomycin was used as the starting material and aluminum chloride was used as a Lewis acid. 4'-O-tetrahydropyran-2-yl-daunomycin was obtained as Compounds (b) and (a). Example 3 (Preparation of 4'-O-tetrahydropyran-2-yl- daunomycin) The same procedure as in Example 1 was performed except that daunomycin was used as the starting material and iron trichloride was used as a Lewis acid. 4'-0-tetrahydropyran- 2-yl-daunomycin was obtained as Compounds (b) and (a). Example 4 Preparation of 4'-O-tetrahydropyran-2-yl14-bromodaunomycin The same procedure as in Example 1 was performed by using 14-bromodaunomycin hydrobromide as the starting material and aluminum tribromide as a Lewis acid. 4'-0-tetrahydropyran-2-yl-14-bromodaunomycin was obtained as Compounds (b) and (a). Example 5 Preparation of 4'-0-tetrahydropyran-2-yl- 14-bromodaunomycin The same procedure as in Example 1 was performed by using 14-bromodaunomycin as the starting material and titanium tetrachloride as a Lewis acid. 4'-0-tetra-hydropyran-2-yl-14-bromodaunomycin was obtained as Compounds (b) and (a). The following table shows the Lewis acid, solvent and reaction temperature used in Examples 2 to 5, as well as the proportion of Compound (b) to Compound (a) formed. Example No. Lewis acid Solvent Temperature (b)/(a) 2 AlCi3 DMF Room temperature 3/1 3 Fecal3 DMF Room temperature 3/2 4 ales DMF Room temperature 2/1 3 5 TiCl4 DMF Room temperature 3/2 As described above, the 4'-O-tetrahydropyranyl derivatives of anthracycline compounds of the formula (Il) prepared by the process of this invention consisted of Compounds (a) and (b), the ratio of Compound (a) to Compound (b) in terms of content being 1:1.5 to 1:3. Thus, this invention provides a process for preparing Compound (b), useful compound, selectively in a larger amount.

Claims: Claims (1) A process for preparing a stereoisomer showing a higher Rf value on silica gel thin-layer chromatography among stereoisomers ascribed to the configuration on the C-2 position of the tetrahydropyran-2-yl group of a 4'-O-tetra- hydropyranyl derivative of an anthracycline compound expressed by the formula EMI9.1 wherein R represents a hydrogen atom, a halogen atom or a protected hydroxyl group, which comprises reacting an anthracycline compound of the formula EMI9.2 wherein R is as defined above, or an acid addition salt thereof, with 3,Il-dihydro-2H-pyran in an inert solvent in the presence of a metal-containing Lewis acid, and isolating the desired stereoisomer by an usual method. (2) The process of Claim (1), wherein the metalcontaining Lewis acid is A1C13, AlBr3, TiC14, or FeC13. (3) The process of claims 1 and 2 wherein the desired isomer is isolated by chromatography.

Inventors: TAKAHASHI, YOSHIKAZU, TAKEUCHI, TOMIO, TATSUTA, KUNIAKI, UMEZAWA, HAMAO, PROF.
Applicants: MICROBIAL CHEMISTRY RESEARCH FOUNDATION
Application year: 1984
Main classification: C07H15
IPC codes: A61P35, A61K31, B01J27, C07B61, C07H15